137 related articles for article (PubMed ID: 23720017)
1. Age related changes in fractional elimination pathways for drugs: assessing the impact of variable ontogeny on metabolic drug-drug interactions.
Salem F; Johnson TN; Barter ZE; Leeder JS; Rostami-Hodjegan A
J Clin Pharmacol; 2013 Aug; 53(8):857-65. PubMed ID: 23720017
[TBL] [Abstract][Full Text] [Related]
2. Assessment of cytochrome P450-mediated drug-drug interaction potential of orteronel and exposure changes in patients with renal impairment using physiologically based pharmacokinetic modeling and simulation.
Lu C; Suri A; Shyu WC; Prakash S
Biopharm Drug Dispos; 2014 Dec; 35(9):543-52. PubMed ID: 25264242
[TBL] [Abstract][Full Text] [Related]
3. Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions.
Greupink R; Schreurs M; Benne MS; Huisman MT; Russel FG
Eur J Pharm Sci; 2013 Aug; 49(5):819-28. PubMed ID: 23806476
[TBL] [Abstract][Full Text] [Related]
4. Prediction of drug-drug interaction potential using physiologically based pharmacokinetic modeling.
Min JS; Bae SK
Arch Pharm Res; 2017 Dec; 40(12):1356-1379. PubMed ID: 29079968
[TBL] [Abstract][Full Text] [Related]
5. Clinical implications of genetic polymorphisms and drug interactions mediated by cytochrome P-450 enzymes.
Touw DJ
Drug Metabol Drug Interact; 1997; 14(2):55-82. PubMed ID: 9893738
[TBL] [Abstract][Full Text] [Related]
6. Impact of Hepatic CYP3A4 Ontogeny Functions on Drug-Drug Interaction Risk in Pediatric Physiologically-Based Pharmacokinetic/Pharmacodynamic Modeling: Critical Literature Review and Ivabradine Case Study.
Lang J; Vincent L; Chenel M; Ogungbenro K; Galetin A
Clin Pharmacol Ther; 2021 Jun; 109(6):1618-1630. PubMed ID: 33283268
[TBL] [Abstract][Full Text] [Related]
7. Use of Developmental Midazolam and 1-Hydroxymidazolam Data with Pediatric Physiologically Based Modeling to Assess Cytochrome P450 3A4 and Uridine Diphosphate Glucuronosyl Transferase 2B4 Ontogeny In Vivo.
Johnson TN; Howgate EM; de Wildt SN; Turner MA; Rowland Yeo K
Drug Metab Dispos; 2023 Aug; 51(8):1035-1045. PubMed ID: 37169511
[TBL] [Abstract][Full Text] [Related]
8.
Tseng E; Lin J; Strelevitz TJ; DaSilva E; Goosen TC; Obach RS
Drug Metab Dispos; 2024 Feb; ():. PubMed ID: 38408867
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes.
Walzer M; Bekersky I; Blum RA; Tolbert D
Pharmacotherapy; 2012 Apr; 32(4):340-53. PubMed ID: 22422635
[TBL] [Abstract][Full Text] [Related]
10. Assessment of a dry extract from milk thistle (Silybum marianum) for interference with human liver cytochrome-P450 activities.
Doehmer J; Weiss G; McGregor GP; Appel K
Toxicol In Vitro; 2011 Feb; 25(1):21-7. PubMed ID: 20828605
[TBL] [Abstract][Full Text] [Related]
11. From preclinical to human--prediction of oral absorption and drug-drug interaction potential using physiologically based pharmacokinetic (PBPK) modeling approach in an industrial setting: a workflow by using case example.
Sinha VK; Snoeys J; Osselaer NV; Peer AV; Mackie C; Heald D
Biopharm Drug Dispos; 2012 Mar; 33(2):111-21. PubMed ID: 22383166
[TBL] [Abstract][Full Text] [Related]
12. Polymorphism of human cytochrome P450 enzymes and its clinical impact.
Zhou SF; Liu JP; Chowbay B
Drug Metab Rev; 2009; 41(2):89-295. PubMed ID: 19514967
[TBL] [Abstract][Full Text] [Related]
13. Assessing the efficiency of mixed effects modelling in quantifying metabolism based drug-drug interactions: using in vitro data as an aid to assess study power.
Johnson TN; Kerbusch T; Jones B; Tucker GT; Rostami-Hodjegan A; Milligan PA
Pharm Stat; 2009; 8(3):186-202. PubMed ID: 19291743
[TBL] [Abstract][Full Text] [Related]
14. Model qualification of the PK-Sim® pediatric module for pediatric exposure assessment of CYP450 metabolized compounds.
Yun YE; Edginton AN
J Toxicol Environ Health A; 2019; 82(14):789-814. PubMed ID: 31405354
[TBL] [Abstract][Full Text] [Related]
15. Optimizing pediatric dosing: a developmental pharmacologic approach.
Anderson GD; Lynn AM
Pharmacotherapy; 2009 Jun; 29(6):680-90. PubMed ID: 19476420
[TBL] [Abstract][Full Text] [Related]
16. Simulations of Cytochrome P450 3A4-Mediated Drug-Drug Interactions by Simple Two-Compartment Model-Assisted Static Method.
Iga K; Kiriyama A
J Pharm Sci; 2017 May; 106(5):1426-1438. PubMed ID: 28089686
[TBL] [Abstract][Full Text] [Related]
17. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation.
Zanger UM; Schwab M
Pharmacol Ther; 2013 Apr; 138(1):103-41. PubMed ID: 23333322
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and risk of potential cytochrome P450-mediated drug-drug interactions in older hospitalized patients with polypharmacy.
Doan J; Zakrzewski-Jakubiak H; Roy J; Turgeon J; Tannenbaum C
Ann Pharmacother; 2013 Mar; 47(3):324-32. PubMed ID: 23482734
[TBL] [Abstract][Full Text] [Related]
19. Detection and prevention of drug-drug interactions in the hospitalized elderly: utility of new cytochrome p450-based software.
Zakrzewski-Jakubiak H; Doan J; Lamoureux P; Singh D; Turgeon J; Tannenbaum C
Am J Geriatr Pharmacother; 2011 Dec; 9(6):461-70. PubMed ID: 22019006
[TBL] [Abstract][Full Text] [Related]
20. Assessment of intestinal availability (FG) of substrate drugs of cytochrome p450s by analyzing changes in pharmacokinetic properties caused by drug-drug interactions.
Hisaka A; Nakamura M; Tsukihashi A; Koh S; Suzuki H
Drug Metab Dispos; 2014 Oct; 42(10):1640-5. PubMed ID: 25061161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
